AnaptysBio Inc (ANAB) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of AnaptysBio Inc $67.84, price $50.77, upside +33.6%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch AnaptysBio Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $8.25 – $69.81 · fair‑value band $39.96 – $82.43 · the $50.77 price screens below the $67.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow AnaptysBio in your weekly email
Every Wednesday you see whether AnaptysBio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Show more
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Stock analysis
AnaptysBio Inc (ANAB) currently trades at $50.77, while our model-based Fair Value estimate is $67.84, implying the stock looks roughly 25.2% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $63.39 per share, and 5 of the 13 models we run sit above the $50.77 price.
Bear case: the Earnings-Based group reads lowest at $21.26, and 8 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: $39.96 (bear) to $82.43 (bull), the price of $50.77 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
AnaptysBio Inc reported revenue of $235M in FY2025 versus $63.2M in FY2021, a compound +38.8%/yr. Reported net income was −$13.2M in FY2025.
Key figures
Market cap $1.7B · P/S ratio 7.44 · EPS (TTM) $−1.02 · Net margin −5.6% · Return on equity −115% · Return on assets (EBIT) −14.9% · Operating margin −136% · Revenue (TTM) $232M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 264% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 34%, ANAB screens cheaper than that median.
Fair Value models
Bear $39.96Fair Value $67.84Bull $82.43
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+157.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+183.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.6%
Start year 2020 (pandemic). Over 10 years: +29.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−31.8% (2020) → 20.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +27.4% a year for the price and +5.1% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside+34% · Top 25%
Profitability
Return on assets7% · Top 25%
Net margin (TTM)−12% · Below median
Operating margin (TTM)−136% · Bottom 25%
Growth and dividend
Revenue growth−8% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AnaptysBio Inc Fair Value". https://www.fairvalue-calculator.com/stock/ANAB
Frequently asked questions
Is AnaptysBio Inc (ANAB) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $67.84 versus a price of $50.77, about +34% upside (undervalued).
What is the fair value of ANAB?
Our model-based fair value for AnaptysBio Inc is $67.84 (as of Sep 24, 2026), built from audited fundamentals. The current price: $50.77.
What is the quality score of ANAB?
AnaptysBio Inc has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AnaptysBio Inc (ANAB)?
Our model-based price target is the fair value of $67.84 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario $39.96, optimistic scenario $82.43. It is a calculation from audited fundamentals, not an analyst target.
What is the AnaptysBio Inc stock forecast for 2026?
Our models put fair value at $67.84, about +34% upside versus a price of $50.77 (undervalued). Cautious scenario $39.96, optimistic scenario $82.43. The calculation is refreshed regularly with new filings.
What is the revenue of AnaptysBio Inc (ANAB)?
AnaptysBio Inc reported trailing-twelve-month revenue of about $232M (latest available figure, as of Sep 24, 2026).
What growth is priced into AnaptysBio Inc (ANAB)?
For today's price to be fair in a discounted-cash-flow model, AnaptysBio Inc would have to grow free cash flow by +30.4 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ANAB use?
Our models discount AnaptysBio Inc at 9.8 %: a base by market capitalisation (small), damped by beta 0.38, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AnaptysBio Inc that is +30.4 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has AnaptysBio Inc (ANAB) delivered so far?
Over the past 5 years revenue at AnaptysBio Inc grew +25.6 % a year. The price currently implies +30.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AnaptysBio Inc (ANAB) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into AnaptysBio Inc (+30.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AnaptysBio Inc (ANAB)?
The free-cash-flow yield on the price is 1.35 %: that much free cash flow AnaptysBio Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AnaptysBio Inc (ANAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AnaptysBio Inc it is $67.84 per share (as of Sep 24, 2026), against a price of $50.77. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is AnaptysBio Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ANAB trades below its calculated fair value: price $50.77, fair value $67.84, a gap of about +34% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANAB?
No. The price is what the market pays today ($50.77); the fair value is what the company's own numbers justify ($67.84). For AnaptysBio Inc the two are $17.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is AnaptysBio Inc worth?
The market values AnaptysBio Inc at about $1.7B (market capitalisation, as of Sep 24, 2026). Per share that is $50.77; our models calculate a fair value of $67.84 per share.
What do the bullish and bearish scenarios say about ANAB?
Our models span a range for AnaptysBio Inc: cautious scenario $39.96, base $67.84, optimistic $82.43 per share (as of Sep 24, 2026, price $50.77). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AnaptysBio Inc (ANAB)?
Balance-sheet figures for AnaptysBio Inc (as of Sep 24, 2026): return on equity −114.6%, debt of 0.02 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is ANAB from its 52-week high?
AnaptysBio Inc trades at $50.77, about 27% below its 52-week high of $69.81 and 264% above the low of $13.97 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $67.84 is for.
Which stocks are comparable to AnaptysBio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AnaptysBio Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $50.77, calculated fair value $67.84 (+34%), Quality Score 67/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANAB calculated?
We run AnaptysBio Inc through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $67.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. AnaptysBio Inc currently trades 34 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AnaptysBio Inc (ANAB)?
The closing price on Sep 23, 2026 was $50.77. Our model-based fair value is $67.84, about +34% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AnaptysBio Inc right now?
Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($39.96 to $82.43) leaves room in how you read the outcome.
Key figures of AnaptysBio Inc
How large is the market capitalisation of AnaptysBio Inc (ANAB)?
The market capitalisation of AnaptysBio Inc is $1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AnaptysBio Inc (ANAB)?
The price-to-sales ratio of AnaptysBio Inc is 7.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AnaptysBio Inc (ANAB)?
Earnings per share at AnaptysBio Inc are $−1.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AnaptysBio Inc (ANAB)?
The net margin of AnaptysBio Inc is −5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AnaptysBio Inc (ANAB)?
The return on equity (ROE) of AnaptysBio Inc is −115% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AnaptysBio Inc (ANAB)?
On an EBIT basis the return on assets of AnaptysBio Inc is −14.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AnaptysBio Inc (ANAB)?
The operating margin of AnaptysBio Inc is −136% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AnaptysBio Inc (ANAB)?
Revenue at AnaptysBio Inc is growing −8.0% versus a year earlier (3y avg +184%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does AnaptysBio Inc (ANAB) hold?
AnaptysBio Inc holds more cash than debt, $224M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch AnaptysBio Inc in the live analysis
One click puts AnaptysBio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026